Efficacy and Safety of T+A+RAD in HCC
This is An Open-label, Single-arm Exploratory Study to determine the efficacy and safety of Multifocal Stereotactic Radiotherapy Combined with Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
RADIATION: Multifocal Stereotactic Radiotherapy|DRUG: Atezolizumab Injection [Tecentriq]|DRUG: Bevacizumab
Objective response rate, ORR, Percentage of Participants with Objective Response According To Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, through study completion, an average of 1 year
Duration of Objective Response (DoR), time interval between objective response to progression, through study completion, an average of 1 year|Disease Control Rate (DCR), CR+PR+SD, through study completion, an average of 1 year|Time to progression (TTP), From screening to the first occurrence of disease progression from any cause up to end of study, through study completion|Progression-free survival (PFS), From screening to the first occurrence of disease progression or death from any cause up to end of study, through study completion|Overall survival (OS), From screening to death from any cause up to end of study, through study completion
This is An Open-label, Single-arm Exploratory Study to determine the efficacy and safety of Multifocal Stereotactic Radiotherapy Combined with Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma